Melanoma Research最新文献_第8页

Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma. 骨髓转移：一项被忽视的恶性黑色素瘤的系统综述。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-08 DOI: 10.1097/CMR.0000000000000942

Giovanni Paolino, Andrea Carugno, Franco Rongioletti, Maurilio Ponzoni, Vincenzo Russo, Paolo Sena, Marco Ardigò, Antonio Costanzo, Santo Raffaele Mercuri, Mario Valenti

{"title":"Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.","authors":"Giovanni Paolino, Andrea Carugno, Franco Rongioletti, Maurilio Ponzoni, Vincenzo Russo, Paolo Sena, Marco Ardigò, Antonio Costanzo, Santo Raffaele Mercuri, Mario Valenti","doi":"10.1097/CMR.0000000000000942","DOIUrl":"10.1097/CMR.0000000000000942","url":null,"abstract":"The occurrence of bone marrow metastases (BMM) in melanoma patients is often underestimated, with only 7% detected during in-vivo staging procedures but rising to 45% in autopsy cases. This systematic review aims to shed light on the clinical and laboratory features of BMM in melanoma by analyzing 73 studies selected from 2 482 initially retrieved from PubMed, Embase , and Cochrane CENTRAL databases. Our findings reveal a slight male predominance, with a median age at BMM diagnosis of 56 years. Primary melanoma sites included the skin (52%), mucosa (8.8%), uvea (20.5%) and unidentified (19%). BMM was preceded by lymph node involvement in 36.5% of cases, whereas 63% showed no nodal metastases, with direct BMM occurring in 22.5% and metastases to other sites in 41%. Common BMM symptoms included pain (60.7%), anemia (80%), thrombocytopenia, leukoerythroblastosis, pancytopenia and leukopenia, while disseminated intravascular coagulation was detected in 11% of cases. In 23.6% of cases, BMM was amelanotic. The prognosis for BMM is grim, with a median survival of only 2 months. Conventional therapies for BMM remain largely ineffective, emphasizing the importance of considering bone marrow as a potential metastatic site in melanoma patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"31-37"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71521971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-10-13 DOI: 10.1097/CMR.0000000000000925

Yuanzhen Cao, Muhammad Zubair Afzal, Edward J Gutmann, Keisuke Shirai

{"title":"Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.","authors":"Yuanzhen Cao, Muhammad Zubair Afzal, Edward J Gutmann, Keisuke Shirai","doi":"10.1097/CMR.0000000000000925","DOIUrl":"10.1097/CMR.0000000000000925","url":null,"abstract":"Pembrolizumab and ipilimumab/nivolumab (ipi/nivo) combination are FDA-approved immune checkpoint inhibitor (ICI) therapies for metastatic melanoma. ICIs could result in various inflammation responses known as immune-related adverse events (IRAEs). We report a patient with metastatic melanoma who developed multiple IRAEs including sarcoidosis-like reaction (SLR), diabetic ketoacidosis (DKA), and worsening hypothyroidism on ICIs. A 71-year-old man with stage IIIC melanoma and lymph node metastasis began adjuvant therapy with pembrolizumab in May 2021. A surveillance positron emission tomography-computed tomography (PET-CT) scan four months later showed diffuse nodal uptake indicating potential metastases although the patient remained asymptomatic. His treatment was temporarily switched to ipi/nivo before biopsy was obtained for definitive diagnosis, which revealed non-caseating granulomas consistent with SLR. After resuming pembrolizumab, he developed DKA and worsening hypothyroidism in November 2021, both of which were attributed to IRAEs. His surveillance PET scan in March 2022 again revealed new hypermetabolic activity in several bones, subcutaneous tissue, and the left inguinal lymph node. Left inguinal node biopsy showed disease recurrence, while biopsies of hypermetabolic subcutaneous nodules and bone demonstrated non-caseating granulomas. Our case described a patient on ICIs who developed several IRAEs. SLR is often asymptomatic but remains a diagnostic challenge due to its indistinguishable appearance on imaging studies compared to metastasis. Better understanding of IRAEs and improved surveillance strategies are needed for optimal patient outcomes.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"70-75"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41205026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance? 恶性黑色素瘤不同转移灶的 BRAF 和 NRAS 状态差异显著，与组织来源和发生时间无关。这是否会影响临床相关性？

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.1097/CMR.0000000000000944

Cameron E Geiger, Salima Mrabet-Dahbi, Irina Berger

引用次数: 0

Impact of anesthesia choice in cutaneous melanoma surgery. 皮肤黑色素瘤手术中麻醉选择的影响。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-02 DOI: 10.1097/CMR.0000000000000936

Matthew G K Benesch, Joseph J Skitzki

{"title":"Impact of anesthesia choice in cutaneous melanoma surgery.","authors":"Matthew G K Benesch, Joseph J Skitzki","doi":"10.1097/CMR.0000000000000936","DOIUrl":"10.1097/CMR.0000000000000936","url":null,"abstract":"Invasive cutaneous melanoma is the most lethal skin cancer, but fortunately, the vast majority can be surgically treated with wide local excision, and sometimes additionally with sentinel or index lymph node biopsy for prognostication. Melanomas are particularly immunogenic malignancies, and preclinical studies have demonstrated that use of volatile anesthetics and opioids, unlike local agents, can suppress the immune system during the perioperative period. Immunosuppression has implications for creating a potentially favorable microenvironment for the survival and propagation of residual melanoma cells or micro-metastases, which could lead to disease relapse, both in the local tumor bed and distally. Results from observational clinical studies are mixed, but the literature would suggest that patients are at risk of decreased melanoma-specific survival after undergoing general anesthesia compared to regional anesthesia and spinal blocks. With the safety of close observation now established rather than automatic completion or total lymph node dissection for patients with either a positive sentinel lymph node biopsy or significant clinical response to neoadjuvant immunotherapy after index node sampling, the indications for definitive surgery with local or regional anesthesia have increased tremendously in recent years. Therefore, cutaneous melanoma patients might benefit from avoidance of general anesthesia and other perioperative drugs that suppress cell-mediated immunity if the option to circumvent systemic anesthesia agents is feasible.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"16-21"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of metastatic bone disease of melanoma. 黑色素瘤转移性骨病的治疗。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-07 DOI: 10.1097/CMR.0000000000000937

Wenyan Chen, Chen Yang, Biqi Chen, Mian Xi, Baoqing Chen, Qiaoqiao Li

引用次数: 0

Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma. 新诊断和复发的III期黑色素瘤患者的辅助抗pd -1治疗的真实无复发生存数据

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-28 DOI: 10.1097/CMR.0000000000000946

Emma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, Yvonne M Schrage, Winan J van Houdt, Alexander C J van Akkooi

{"title":"Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.","authors":"Emma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, Yvonne M Schrage, Winan J van Houdt, Alexander C J van Akkooi","doi":"10.1097/CMR.0000000000000946","DOIUrl":"10.1097/CMR.0000000000000946","url":null,"abstract":"We aimed to compare the relapse-free survival (RFS) in patients treated with adjuvant anti-programmed cell death-1 (anti-PD-1) therapy for a first diagnosis of stage III melanoma to patients treated after resection of the recurrences. Patients treated with adjuvant anti-PD-1 therapy after complete resection of stage III melanoma between September 2018 and January 2021, were included. Depending on when adjuvant anti-PD-1 treatment was initiated, patients were divided over 2 cohorts: for the first diagnosis (cohort A) or for a second or subsequent diagnosis (cohort B) of stage III melanoma. Clinical data and RFS were compared between cohorts. 66 patients were included: 37 in cohort A, 29 in cohort B. Median follow-up time from the start of adjuvant therapy was 21 months and 17 months in cohorts A and B, respectively. Significant differences in ulceration of the primary tumor ( P = 0.032), stage according to the 7th AJCC (American Joint Committee on Cancer , P = 0.026) and type of metastatic involvement ( P = 0.005) were found between cohorts. In cohorts A and B, 18 (49%) and 8 (28%) patients developed a recurrence and the 1-year RFS was 51% and 72%, respectively. In cohort B, RFS remained longer in the patients of which the interval between first diagnosis of stage III melanoma and start of adjuvant therapy was >48 months compared to ≤48 months (83% vs. 65%, P = 0.253). This study demonstrates that patients with recurrent stage III disease, not previously treated with adjuvant systemic therapy, may derive similar benefit to a first diagnosis of stage III patients if access to adjuvant therapy changes.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"63-69"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS. cobimetinib和vemurafenib在德国现实条件下BRAF V600突变黑色素瘤伴和不伴脑转移患者中的有效性、安全性和利用率:非介入性研究coveNIS。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-13 DOI: 10.1097/CMR.0000000000000908

Katharina C Kähler, Dirk Debus, Gaston Schley, Daniela Göppner, Jessica C Hassel, Friedegund Meier, Patrick Terheyden, Rudolf Stadler, Thomas Tüting, Martin Kaatz, Norman-Philipp Hoff, Ehsan Masoudi, Agnieszka Zdanowicz-Specht, Minh Tam Nguyen, Peter Mohr

{"title":"Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.","authors":"Katharina C Kähler, Dirk Debus, Gaston Schley, Daniela Göppner, Jessica C Hassel, Friedegund Meier, Patrick Terheyden, Rudolf Stadler, Thomas Tüting, Martin Kaatz, Norman-Philipp Hoff, Ehsan Masoudi, Agnieszka Zdanowicz-Specht, Minh Tam Nguyen, Peter Mohr","doi":"10.1097/CMR.0000000000000908","DOIUrl":"10.1097/CMR.0000000000000908","url":null,"abstract":"Cobimetinib/vemurafenib combination therapy is approved for treatment of adults with unresectable or metastatic BRAF V600 mutated malignant melanoma (mM). The non-interventional post-authorisation safety study coveNIS collected real-world data on cobimetinib/vemurafenib treatment focussing on overall survival (OS), safety and utilization. MM patients with brain metastases are usually excluded from clinical studies. coveNIS observed 2 cohorts: mM patients without (Cohort A) and with cerebral metastases (Cohort B), aiming to close the data gap for the latter population. A direct comparison of the 2 cohorts was not intended. The primary effectiveness objective was OS; the safety objective was the incidence of all and of serious adverse events (AEs). Secondary objectives included progression-free survival (PFS), time to development of cerebral metastasis (Cohort A) and time to central nervous system relapse (Cohort B). All statistical analyses were descriptive. Between 2017 and 2021, 95 patients were included (Cohort A: 54, Cohort B: 41 patients) at 32 sites in Germany. Median OS was 21.6 months in Cohort A, 7.4 months in Cohort B. Median PFS was 6.9 months in Cohort A, 5.2 months in Cohort B. The proportion of patients experiencing any AEs was 83.3% (Cohort A) and 87.8% (Cohort B). The two most common AEs in Cohort A were 'diarrhoea' (37%), 'vomiting' (20.4%) and 'pyrexia' (20.4%); in Cohort B 'diarrhoea' (36.6%) and 'fatigue' (22%). In conclusion, the OS rates in Cohort A and Cohort B of coveNIS are in line with the OS data from other trials with BRAF/MEK inhibitors for mM. No new safety signals were observed.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"44-53"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92155294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis. 家族性黑色素瘤患者CDKN2A种系突变的预后：一项系统综述和荟萃分析。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-02 DOI: 10.1097/CMR.0000000000000920

Ana Taibo, Sabela Paradela, Jorge Suanzes-Hernández, Vanesa Balboa-Barreiro, Javier Amado-Bouza, Eduardo Fonseca

{"title":"Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.","authors":"Ana Taibo, Sabela Paradela, Jorge Suanzes-Hernández, Vanesa Balboa-Barreiro, Javier Amado-Bouza, Eduardo Fonseca","doi":"10.1097/CMR.0000000000000920","DOIUrl":"10.1097/CMR.0000000000000920","url":null,"abstract":"Familial melanoma is defined as melanoma occurring in two or more first-degree relatives by the WHO. Germline mutations are isolated in a subset of them. It is well known that CDKN2A is the most frequently mutated high-risk gene in familial melanoma, however, the prognosis it confers to patients who carry its mutations is still controversial. This review aims to assess whether germline mutations imply a worse prognosis in patients with familial melanoma. A systematic review and meta-analysis were conducted by searching the electronic databases PubMed/MEDLINE, EMBASE, and Cochrane Library. Data from 3 independent populations were eventually included in the meta-analysis, involving 291 cases and 57 416 controls. The results of this systematic review and meta-analysis suggest that there is a tendency for patients with germline mutations in the CDKN2A gene to have a worse overall survival (HR = 1.30, 95% CI = 0.99-1.69, P = 0.05) and melanoma-specific survival (HR = 1.5, 95% CI = 0.97-2.31, P = 0.07). Carrier patients would not only have more incidence of melanoma and a higher risk of a second melanoma, but they also seem to have a worse prognosis. The inclusion of gene panel testing in clinical practice and the collaboration within consortia are needed to provide further evidence on the prognosis of these patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"9-15"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies. 靶向治疗下BRAF突变黑色素瘤患者的瘤内和全身炎症作为治疗反应的预测因素。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-02 DOI: 10.1097/CMR.0000000000000934

Thilo Gambichler, Maria Iordanou, Jürgen C Becker, Laura Susok

{"title":"Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.","authors":"Thilo Gambichler, Maria Iordanou, Jürgen C Becker, Laura Susok","doi":"10.1097/CMR.0000000000000934","DOIUrl":"10.1097/CMR.0000000000000934","url":null,"abstract":"Intratumoural as well as systemic inflammation in melanoma has thoroughly been studied in the context of patients treated with immune checkpoint inhibitors but not with BRAF/MEK inhibitors (BRAFi/MEKi). We aimed to study whether parameters of intratumoral and systemic inflammation correlate with clinical outcome in patients with BRAF-mutant metastatic melanoma treated with BRAFi/MEKi. We studied 51 CM patients with unresectable stage III or IV who had the indication for BRAFi/MEKi treatment based on confirmed BRAF mutation. Baseline systemic immune-inflammation markers such as the systemic immune-inflammation index (SII) and the expression of intratumoral inflammation markers such as COX-2 protein expression were correlated with clinical outcome measures. On multivariable analyses, lower intratumoral COX-2 expression (OR 33.9, 95% CI 3.2-356.8) and lower SII (OR 6.3, 95% CI 1.1-34.8) proved to be significant independent predictors for objective response to targeted therapy. Elevated S100B (HR 1.2, 95% CI 1.03-1.3) was a significant predictor for progressive disease. Moreover, elevated S100B (HR 1.37, 95% CI 1.14-1.65) and LDH (HR 1.002, 95% CI 1.0001-1.003) were significant independent predictors for melanoma-specific death. In conclusion, the present study indicates that low SII values and low intratumoral COX-2 protein expression are significant independent predictors for treatment response to BRAFi/MEKi.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"80-83"},"PeriodicalIF":2.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71483547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report. 伊匹单抗后小血管炎导致严重急性肾损伤:1例报告。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-02-01 Epub Date: 2023-11-28 DOI: 10.1097/CMR.0000000000000928

Rui Duarte, Filipa Trigo, Ivan Luz, Paulo Santos

引用次数: 0